Evidence map›Paper›PMID 41388181›Full record

ArticleJournal of computer-aided molecular design2025

Molecular simulations of paclitaxel binding to mutant β-tubulin: insights into chemotherapy resistance.

Paola Vottero, Martina Centroni, Ebenezea Gitari, Philip Winter, Jack Tuszynski, Maral Aminpour

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of computer-aided molecular design, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Paola Vottero *Department of Biomedical Engineering, University of Alberta, Edmonton, T6G 1H9, Canada.
Martina Centroni *DIMEAS, Politecnico di Torino, Corso Duca degli Abruzzi 24, Torino, 10129, Italy.
Ebenezea GitariDepartment of Biomedical Engineering, University of Alberta, Edmonton, T6G 1H9, Canada.
Philip WinterDepartment of Biomedical Engineering, University of Alberta, Edmonton, T6G 1H9, Canada.
Jack TuszynskiDIMEAS, Politecnico di Torino, Corso Duca degli Abruzzi 24, Torino, 10129, Italy.
Maral AminpourDepartment of Biomedical Engineering, University of Alberta, Edmonton, T6G 1H9, Canada. aminpour@ualberta.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Paclitaxel, a cornerstone in cancer chemotherapy, stabilizes microtubules by binding to the β-tubulin taxane site. However, resistance mechanisms, often driven by β-tubulin mutations, undermine its efficacy. While such mutations are known to alter drug sensitivity, their molecular impact on paclitaxel binding remains incompletely understood. Here, we employ molecular docking, molecular dynamics (MD) simulations, and Molecular Mechanics with Generalized Born Surface Area (MM/GBSA) calculations to quantify how clinically relevant β-tubulin mutations affect paclitaxel binding affinity. Root mean square fluctuation (RMSF) analysis was used to assess local structural dynamics near the binding site. Our results show that despite minor variations in docking scores, MM/GBSA analyses revealed significant mutation-induced shifts in binding free energy, particularly for residues near the M loop, H5-H6 helices, and S9-S10 region. Complementary RMSF analysis indicated altered flexibility in several of these regions, suggesting potential disruptions to local stabilization mechanisms. Differences between single- and two-dimer simulations highlight the importance of modeling lateral protofilament contacts when evaluating microtubule-targeting agents. These findings underscore the relevance of structure-based modeling for understanding drug resistance mechanisms and informing the development of mutation-aware taxane therapies.

Indexed as

Antineoplastic Agents, PhytogenicDrug Resistance, NeoplasmPaclitaxelTubulinBinding SitesHumansMicrotubulesMolecular Docking SimulationMolecular Dynamics SimulationMutationProtein BindingThermodynamicsAntineoplastic Agents, PhytogenicPaclitaxelTubulinChemotherapy resistanceMolecular dynamics simulationsPaclitaxelΒ-tubulin mutations

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.